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ABSTRACT
Recent evidence demonstrated CIN4 as a predictive marker of anthracycline 
benefit in early breast cancer. An analysis of the NCIC CTG MA.21 clinical trial was 
performed to test the role of existing CIN gene expression signatures as prognostic 
and predictive markers in the context of taxane based chemotherapy.
RNA was extracted from patients in cyclophosphamide, epirubicin and fluorouracil 
(CEF) and epirubicin, cyclophosphamide and paclitaxel (EC/T) arms of the NCIC CTG 
MA.21 trial and analysed using NanoString technology.
After multivariate analysis both high CIN25 and CIN70 score was significantly 
associated with an increased in RFS (HR 1.76, 95%CI 1.07-2.86, p=0.0018 and HR 
1.59, 95%CI 1.12-2.25, p=0.0096 respectively). Patients whose tumours had low 
CIN4 gene expression scores were associated with an increase in RFS (HR: 0.64, 95% 
CI 0.39-1.03, p=0.06) when treated with EC/T compared to patients treated with CEF.
In conclusion we have demonstrated CIN25 and CIN70 as prognostic markers 
in breast cancer and that CIN4 is a potential predictive maker of benefit from taxane 
treatment.
INTRODUCTION
Taxanes and anthracyclines are widely used for the 
treatment of breast cancer yet highly toxic to patients 
[1–4]. At present there is no biological marker or assay 
available to identify which subset of patients will benefit 
from chemotherapy although numerous molecules have 
been investigated with limited success [4–12]. Research 
from our group [8] linked the predictive effect of CEP17 
in vivo to chromosome instability (CIN), which itself is 
predictive of anthracycline benefit in the BR9601 trial 
[8]. We recently derived a four gene signature that was 
predictive of anthracycline benefit and demonstrated 
that patients with low tumour CIN4 scores benefited 
from anthracycline treatment significantly more than 
those with high CIN4 scores (HR 0.37, 95% CI 0.20-
0.56, p=0.001) [13]. Given that most patients now 
receive taxane based chemotherapy we sought to 
extend the validation of this marker into trials including 
taxanes.
The NCIC Clinical Trials Group (CTG) MA.21 trial 
compared dose-intense cyclophosphamide, epirubicin and 
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fluorouracil (CEF) to dose-dense, dose-intense epirubicin, 
cyclophosphamide with added paclitaxel (EC/T) and to a 
standard at the time of doxorubicin, cyclophosphamide 
and paclitaxel (AC/T). Analyses comparing the two 
epirubicin arms of the trial (CEF vs EC/T) did not 
demonstrate benefit from the addition of taxane (EC/T vs 
CEF) in terms of relapse free survival (RFS) (HR 0.85, 
95% CI 0.64-1.22, p=0.46) [14].
Our present study, we evaluated the predictive 
effect of the CIN signatures in patients in the NCIC 
CTG MA.21 trial and hypothesized that CIN signatures 
are associated with clinical outcome and resistance to 
taxane therapy.
RESULTS
Characteristics
Table 1 shows the baseline characteristics of the 
MA.21 CIN study population, whereas Figure 1 illustrates 
the total number of cases available for analysis; 342 RNA 
samples from CEF arm and 336 RNA samples from the 
ECT arm were successfully analysed on the NanoString 
platform. High CIN4, CIN25 and CIN70 scores were 
defined as above the median and were previously 
described [15–13].
Correlation of CIN signatures and 
clinicopathological parameters  
with clinical outcomes
In univariate analysis using continuous clinico-
pathological biomarkers, high CIN4 was associated with 
ER positivity (p<0.0001) and grade (p<0.001), whereas 
CIN25 and CIN70 were associated with younger age 
(p=0.01 and p=0.001, respectively), increase in the number 
of positive axillary nodes (p<0.0001) and ER negativity 
(p<0.0001) (Table 2).
CIN signatures as a prognostic marker for RFS
The prognostic impact of the CIN signatures were 
tested on the entire cohort, irrespective of allocated 
adjuvant chemotherapy. No statistically significant 
association was observed between CIN4 or CIN70 
scores and RFS (HR: 1.11, 95% CI 0.79-1.55, p=0.548 
and HR: 0.73, 95% CI 0.52-1.02, p=0.07, (Figure 
2A) respectively). In contrast, tumours with high 
CIN25 scores were associated with increased RFS 
(HR: 1.52, 95%CI 2.13-10.64, p=0.02) (Figure 2B). 
After multivariate analysis and adjustment for nodal 
status, grade, size, age, HER2 and ER status, both high 
CIN25 and CIN70 scores were significantly associated 
with an increased RFS (HR 1.76, 95%CI 1.07-2.86, 
p=0.0018 and HR 1.59, 95%CI 1.12-2.25, p=0.0096 
respectively).
CIN signatures as predictive markers of taxane 
benefit
Subsequent analysis focused on the differential 
impact of multigene signatures on RFS between patients 
receiving anthracycline plus taxane (EC/T) therapy 
and those given anthracycline treatment (CEF) alone. 
Univariate analysis demonstrated no significant difference 
in benefit from ECT versus CEF treatment between 
patients whose tumours had high (HR 0.79, 95%CI 0.51-
1.23, p=0.30) or low CIN70 expression (HR 1.30, 95% 
CI 0.76-2.21, p=0.34) (Table 3). Similarly there was no 
differential benefit from ECT treatment between patients 
whose tumours had high (HR 0.78, 95%CI 0.51-1.20, 
p=0.26) or low CIN25 expression (HR 1.35, 95% CI 0.78-
2.34, p=0.28).
The hazard ratio for treatment by marker interaction 
of CIN25 and CIN70 before correction for clinical variables 
was 0.58 (95% CI 0.29-1.17, p=0.128) and 0.61 (95% CI 
0.31-1.122, p=0.166), respectively. After correction for size, 
nodal status, ER status, HER2, grade, CIN4 and treatment, 
the hazard ratio was 0.64 (95% CI 0.29-1.40, p=0.263) and 
0.70 (95% CI 0.33-1.50, p=0.355) for CIN25 and CIN70, 
respectively. However, a trend was noted in patients whose 
tumours had low CIN4 gene expression scores with an 
increase in RFS (HR: 0.64, 95% CI 0.39-1.03, p=0.06) 
when treated with EC/T compared to patients treated 
with CEF (Figure 3). There was no statistical significant 
difference in survival in patients that has high CIN4 gene 
expression scores (HR: 1.54, 95% CI 0.1-2.57, p=0.107). 
The hazard ratio for treatment by marker interaction of 
CIN4 before correction for clinical variables was 0.49 (95% 
CI 0.25-0.97, p=0.04) for RFS. After correction for size, 
nodal status, ER status, HER2, grade, CIN4 and treatment, 
the hazard ratio was 0.49 (95% CI 0.23-1.05, p=0.066).
DISCUSSION
CIN is associated with poor prognosis in patients 
with solid tumours [16–15]. We have previously shown 
that CIN is associated with sensitivity to anthracycline 
treatments [8–13] while others have demonstrated that 
CIN is associated with taxane resistance [17]. Since 
modern chemotherapy treatment of breast cancer 
includes the addition of a taxane, we examined the role 
of three CIN gene signatures in the NCIC CTG MA.21 
breast cancer trial that compares taxane versus no-
taxane containing arms. Our study has demonstrated that 
patients with low expression of the CIN4 gene signature 
exhibited greater benefit from the EC/T treatment 
regimen versus the CEF regimen. This is in contradiction 
to previous work in ovarian cancer suggesting a CIN70 
gene expression signature was predictive of resistance 
to taxanes and sensitivity to carboplatin treatment [17]. 
However, it is unclear if our current result reflects the 
addition of a taxane to the treatment regimen or simply 
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extending the duration of the chemotherapy regimen. 
Both arms included a cumulative dose of 720mg/m2 of 
epirubicin however; the EC/T arm had an additional four 
cycles of paclitaxel [14]. Therefore, our result could 
reflect either the addition of paclitaxel or the need for 
extended chemotherapy. However, there is accumulating 
evidence to support the former. For example, the UK 
TACT study investigated whether sequential docetaxel 
after anthracycline chemotherapy would improve patient 
outcome compared to standard chemotherapy of a 
similar duration. This study demonstrated no difference 
in disease free survival between the FEC-D group and 
Table 1: Baseline patient and tumour characteristics from the MA.21 study
Baseline characteristics CEF
342 (100%)
ECT
336 (100%)
Age
≤39 56 (16.4%) 59 (17.6%)
40-49 159 (46.5%) 146 (43.4%)
50-59 126 (36.8%) 128 (38.1%)
60-69 1 (0.3%) 3 (0.9%)
Median
Menopausal status
Post-menopausal 102 (29.8%) 101 (30.1%)
Pre-menopausal 240 (70.2%) 235 (69.9%)
#of positive axillary nodes
0 109 (31.9%) 102 (30.4%)
1-3 136 (39.8%) 146 (43.5%)
4-10 79 (23.0%) 72 (21.4%)
>10 18 (5.3%) 16 (4.7%)
Tumour stage
T1 108 (31.6%) 114 (34.2%)
T2 200 (58.5%) 177 (53.2%)
T3 30 (8.8%) 37 (11.1%)
T4 4 (1.1%) 5 (1.5%)
Missing 3
ER Status
Positive 195 (57.0%) 196 (58.3%)
Negative 147 (43.0%) 140 (41.7%)
CIN4
High 161 (47.1%) 164 (48.9%)
Low 181 (52.9%) 173 (51.1%)
CIN25
High 183 (53.5%) 186 (55.2%)
Low 159 (46.5%) 151 (44.8%)
CIN70
High 181 (52.9%) 186 (55.2%)
Low 161 (47.1%) 151 (44.8%)
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the control group (HR 0.95, 95% CI 0.85-1.08, p=0.44) 
[18]. Meta-analyses performed by the EBCTCG group 
demonstrated the incorporation of taxanes into an 
anthracycline regimen resulted in the reduction of the 
risk of recurrence and survival at 8 years [19]. This 
analysis recognised there was variation in trial designs 
when comparing the effects of additional cycles of just a 
taxane to a constant background chemotherapy regimen. 
However, in the taxane trials with different number of 
cycles the 8-years breast cancer mortality was 21.1% 
for the taxane groups versus 23.9% for the control 
groups. In contrast in trials examining the effects of a 
taxane regimen with the same number of cycles non-
taxane chemotherapy demonstrated the 5-year a small 
but significant reduction in breast cancer mortality [19]. 
These results would indicate that the addition of a taxane 
to the chemotherapy regimen improves survival and the 
CIN4 is predictive of taxane benefit.
In agreement with other studies, we have 
demonstrated that the CIN25 and CIN70 signature 
is an independent prognostic biomarker in breast 
cancer [15–20]. We performed our analysis on the 
Figure 1: REMARK diagram for the evaluation of chromosome instability (CIN) gene expression signatures in the 
NCIC CTG MA.21 trial.
Table 2: Correlations between CIN scores and conventional pathological markers
CIN4 CIN25 CIN70
Age NS -0.128p=0.01
-0.131
p=0.001
Positive axillary node NS -0.246p<0.001
-0.226
p<0.001
Tumour size NS NS NS
Grade
-0.195
p<0.001
0.528
p<0.001
0.500
p<0.001
ER 0.092p=0.017
-0.430
p<0.001
-0.413
p<0.001
HER2 NS NS NS
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Figure 2: Kaplan-Meier survival curves for low CIN70 score (green line) and high CIN70 score (blue line) for relapse 
free survival. A. Kaplan-Meier survival curves for low CIN25 score (green line) and high CIN25 score (blue line) for relapse free survival 
B.
Table 3: Hazard ratios for relapse free survival comparing cyclophosphamide, epirubicin and fluorouracil (CEF) 
with cyclophosphamide, epirubicin and paclitaxel (EC/T) by biomarker status
Relapse Free Survival
Low Biomarker High Biomarker Treatment*Marker
HR 95% CI HR 95% CI HR Test for 
Interaction P
CIN70 1.30 0.76-2.21 0.79 0.51-1.23 1.43 0.355
CIN25 1.35 0.78-2.34 0.78 0.51-1.20 1.57 0.263
CIN4 0.64 0.39-1.03 1.53 0.91-2.57 0.49 0.066
Figure 3: Kaplan-Meier survival curves for cyclophosphamide, epirubicin and fluorouracil (CEF, blue) treated 
with cyclophosphamide, epirubicin and paclitaxel (EC/T, green line) for relapse free survival stratified by low CIN4 
expression. A. and high CIN4 expression B.
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NanoString platform, which has been shown to be a 
robust and reproducible platform that can easily be 
incorporated into the pathology laboratory setting [21]. 
The identification of methods that predict breast cancer 
clinical outcome is being studied in numerous labs 
around the world. There are a number of prognostic 
expression arrays available such as Oncotype DX 
[22], Mammaprint [23] and Prosigna [21] that predict 
patient outcome in estrogen receptor (ER) positive 
patients; however, none of them are tailored towards 
the ER negative population. The CIN25 and CIN70 
gene expression signatures were derived irrespective of 
ER status and contain genes, such as TPX2, TOP2A, 
MAD2L1, CCNB1, CDC20 and PTTG1 that are 
involved in spindle assembly checkpoint (SAC) as well 
as DNA damage checkpoint genes [15]. Therefore, the 
CIN25 and CIN70 signatures are credible candidates for 
use in the prognostic setting.
Ultimately, although there are a number of 
prognostic markers available, but there are no predictive 
signatures associated with specific chemotherapies to level 
I evidence. We had previously demonstrated the CIN4 
signature to be predictive of anthracycline benefit [13], 
in this study we demonstrate that CIN4 has potential to 
be predictive for benefit from the addition of a taxane to 
chemotherapy treatment.
MATERIALS AND METHODS
Patients
The MA.21 (ClinicalTrials.gov (NCT00014222)) 
trial recruited 2104 pre- and post-menopausal women 
with histologically confirmed node positive or high risk 
node negative adenocarcinoma of the breast treated 
with either total or partial mastectomy. Patients were 
randomised to one of three regimens to receive: 1) 6 
cycles of CEF (epirubicin (60mg/m2) and fluorouracil 
(500mg/m2) given intravenously on days 1 and 8 and 
oral cyclophosphamide (75mg/m2) on days 1-14) every 
28 days, 2) 6 cycles of EC/T (epirubicin (120mg/m2) and 
cyclophosphamide (830mg/m2) on day 1 and filgrastim 
(G-CSF) subcutaneously (SC) on days 2-13 followed by 4 
cycles of paclitaxel (175mg/m2)) every 21 days, 3) 4 cycles 
of AC/T (doxorubicin (60mg/m2) and cyclophosphamide 
(600mg/m2) on day 1 every 21 days followed by 4 cycles 
of paclitaxel (175mg/m2)) every 21 days. Treatment in all 
arms continued in the absence of disease progression or 
unacceptable toxicity; patient characteristics are shown 
in Table 1. The primary end point for the MA.21 trial 
was relapse-free survival (RFS) defined as the time from 
randomization to the time of recurrence of the primary 
disease. The protocol was approved by central and local 
ethics committees, and each patient provided written 
informed consent prior to randomization. For the current 
analysis, tissue blocks were retrieved for RNA extraction.
RNA extraction
Total RNA from FFPE tissue samples (2 x 10µM 
sections) was extracted using the RecoverAll Total 
Nucleic Acid Isolation kit (Life Technologies) according 
to the manufacturer’s protocol and concentrations 
were determined using the NanoDrop ND-1000 
spectrophotometer (NanoDrop Technologies).
Gene expression analysis
RNA (200ng) was used with the nCounter 
system, according to the manufacturer’s protocol 
(NanoString ® Technologies, Seattle, WA, USA). In 
brief, 5µl of RNA was hybridized at 96oC overnight 
with the NanoString Codeset. Probes for the analysis 
were synthesized by NanoString technologies and 
included probes for the 93 genes of interest and 6 
normalising genes (Supplementary Table S1); all 99 
genes were assayed simultaneously in multiplexed 
reactions. After probe hybridizations and NanoString 
nCounter digital reading, counts for each RNA species 
analyzed. The nCounter CodeSet contains two types 
of built-in controls: positive controls (spiked RNA 
at various concentrations to assess the overall assay 
performance) and negative controls (probes for 
background calculation). Raw mRNA abundance count 
data were pre-processed using the NanoStringNorm R 
package (v1.1.19) using normalization factors derived 
from the geometric mean of housekeeping genes, mean 
of negative controls and geometric mean of positive 
controls [24]. The CIN4/25/70 scores were developed 
and analysed as described in [13].
Statistics
The SAS (SAS Institute Inc., Cary, NC, USA, 
version 9.2) statistical package was used for statistical 
analysis. Kaplan-Meier curves of survival were used 
for estimation of relapse free survival (RFS), whereas 
log-rank test was used to compare RFS among different 
groups of patients. The Cox proportional hazards 
model was used to estimate hazard ratios for relapse. 
When comparing outcomes between the treatment arms 
within the groups of patients identified by biomarker 
expression, p-values were not calculated for sub-
groups to avoid multiple testing and bias where one 
group was much smaller than the other. The Cox model 
was instead used to identify statistically significant 
interactions (p<0.05) between biomarkers and outcome 
on the different treatments (treatment by marker 
interaction), in models that also included biomarker 
status (marker effect) and treatment, as covariates. In 
exploratory analyses a value of p<0.05 was considered 
statistically significant as the Bonferroni correction was 
not applied.
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